

1 **Title page**

2 **Evaluation of seven different rapid methods for nucleic acid detection of SARS-COV-2 virus**

3 **Running title: Rapid methods for nucleic acid detection of SARS-COV-2 virus**

4 **Authors' details**

5 1.Dr. Sally A. Mahmoud (Corresponding author)

6 Director, Biogenix Lab G42, Abu Dhabi, UAE

7 Email ID: sally.abdulla@g42.ai

8 2.Ms. Esra Ibrahim

9 Quality Manager, Biogenix Lab G42, Abu Dhabi, UAE

10 Email ID: esra.ibrahim@g42.ai

11 3.Dr. Subhashini Ganesan

12 Research Assistant, G42 Healthcare, UAE

13 Email ID: Subhashini.g@g42.ai

14 4.Dr. Bhagyashree Thakre

15 Specialist Pathologist, Biogenix Lab G42, Abu Dhabi, UAE

16 Email ID: bhagyashree.thakre@g42.ai

17 5.Dr.Juliet George Teddy

18 Specialist Pathologist, Biogenix Lab G42, Abu Dhabi, UAE

19 Email ID : juliet.teddy@g42.ai

20 6.Mrs.Preeti Raheja

21 Quality Manager, Biogenix Lab G42, Abu Dhabi, UAE

22 Email ID: Preety.Raheja@g42.ai

23 7.Dr.Walid Abbas Zaher

24 Chief Research Officer, G42 Healthcare, UAE

25 Email ID : Walid.Zaher@g42.ai

26

27 **Main manuscript**

28 **Abstract**

29 Background

30 In the current COVID-19 pandemic there is mass screening of SARS-CoV-2 happening round the
31 world due to the extensive spread of the infections. There is a high demand for rapid diagnostic
32 tests to expedite identification of cases and to facilitate early isolation and control spread. Hence
33 this study evaluates seven different rapid nucleic acid detection assays that are commercially
34 available for SARS- CoV- 2 virus detection.

35 Methods

36 Nasopharyngeal samples were collected from 4859 participants and were tested for SARS-CoV-2
37 virus by the gold standard RT-PCR method along with one of these seven rapid methods of
38 detection. Evaluation of the rapid nucleic acid detection assays was done by comparing the results
39 of these rapid methods with the gold standard RT-qPCR results for SARS-COV-2 detection.

40 Results

41 AQ-TOP had the highest sensitivity (98%) and strong kappa value of 0.943 followed by
42 Genechecker and Abbot ID NOW. The POCKIT (ii RT-PCR) assay had the highest test accuracy
43 of 99.29% followed by Genechecker and Cobas Liat. Atila iAMP showed the highest percentage
44 of invalid reports (35.5%) followed by AQ-TOP with 6% and POCKIT with 3.7% of invalid
45 reports.

46 Conclusion

47 Genechecker system, Abbott ID NOW and Cobas Liat, were found to have best performance and
48 agreement when compared to the standard RT-PCR for COVID-19 detection. With further
49 research, these rapid tests have the potential to be employed in large scale screening of COVID-
50 19.

51 Keywords: COVID-19; SARS-CoV-2; rapid tests; nucleic acid tests

52 **Background**

53 The COVID-19 pandemic has affected more than 112 million people worldwide and continues to
54 spread and remains a public health challenge. [1] The real-time reverse-transcription PCR (RT-
55 PCR) remains the gold standard for testing SARS- COV- 2 and is approved by both the WHO and
56 CDC. But this method requires a well-established lab set up, expensive instruments, well trained
57 and skilled manpower and long hours. In the current scenario of the pandemic, with such large
58 numbers being affected conducting these tests with limited lab capacities is challenging. [2] The
59 lab facilities are overburdened, and molecular testing is time consuming which delays reporting
60 and that in turn limits the containment of spread. [3] Hence there is a demand for alternative testing
61 strategies that are rapid and less sophisticated. [4].

62 In SARS-CoV-2 human-to-human transmission is through droplets or direct contact [5] and its
63 symptoms are very similar to flu, hence molecular tests are critical to differentiate and detect
64 COVID-19 infections. In the early stages of infection, the viral load is usually high in patients and
65 studies show that a single swab can contain more than a million viral particles,[6] hence nucleic
66 acid testing is the most efficient form of testing in the early stages, and identifying infections earlier
67 is vital. As mass testing, early detection and isolation are crucial for containing the spread of
68 infection, evaluation of these rapid tests becomes imperative.

69 Currently there are many nucleic acid detection assays that have obtained emergency authorization
70 by FDA to detect SARS-COV-2 and have been largely implemented around the globe.
71 The study compares seven different molecular tests that detects nuclear RNA of SARS- COV- 2
72 and evaluates them against the standard RT-PCR.

73 **Materials and Methods**

74 This study obtained ethical approval from the IRB of Department of Health (DOH), Abu Dhabi.
75 The study was conducted among people who were admitted in the COVID-19 field hospital and
76 among people who were getting screened for COVID-19 infections in the laboratory. After getting
77 informed consent from the participants nasopharyngeal swabs (NPS) were collected from the study
78 participants. For the wet swab, a sterile swab was used for collection and then was placed into the
79 universal transport medium (UTM). An additional dry swab was collected from participants who
80 were willing to give an additional sample. All samples that were collected outside the lab were
81 transported to the lab immediately and samples that were not processed immediately were stored
82 at -80 degree Celsius.

83 A total of 5181 participants were tested for SARS-CoV-2 virus by the gold standard RT-PCR
84 method for SARS-CoV-2 detection and with one of these seven rapid methods of detection. The
85 rapid tests were evaluated by comparison the rapid nucleic acid detection assays results with the
86 standard RT-PCR results for SARS-COV-2 detection. Of these seven rapid detection methods, two
87 were based on loop isothermal nucleic acid amplification technology (Abbott ID NOW, AQ-TOP),
88 one on OMEGA amplification (Atila iAMP), one direct RT-PCR without RNA extraction method
89 (Direct NPS), one based on insulated isothermal polymerase chain reaction (iiPCR) technology,
90 one on automated multiplex real-time RT-PCR assay (Cobas Liat) and one based on microfluidic
91 chip-based PCR method (Genechecker).

92 **The seven rapid nucleic acid detection assays**

93 **The Abbott ID NOW COVID-19 assay [7]** - 689 samples were tested using this method. It is an
94 automated assay that utilizes isothermal nucleic acid amplification technology for the qualitative
95 detection of nucleic acid from the SARS-CoV-2 virus from nasopharyngeal swabs from
96 individuals who are suspected of COVID-19. It detects the RNA-dependent RNA polymerase
97 (RdRp) gene segment of SARS-CoV-2 and is performed on the ID NOW instrument. Fluorescently
98 labeled molecular beacons are used to specifically identify each of the amplified RNA targets. The
99 testing was performed as per manufacturer's instructions. It takes 1- 2 minutes active preparation
100 and the time to result is about 13 minutes. It has received FDA emergency authorization for use.
101 [8] In this study, the testing was done onsite for detecting SARS-COV-2 from a dry swab collected
102 from the participants. Results are directly displayed on the screen as positive or negative along
103 with the internal control validity.

104

105 **Atila iAMP COVID- 19 detection [9]** – 197 samples were tested using this method, which is a
106 real-time reverse transcription based on a proprietary isothermal amplification technology termed
107 OMEGA amplification. OMEGA primer sets are designed to specifically detect RNA and later
108 cDNA from the N and ORF-1ab genes of the SARSCoV-2 virus in nasal, nasopharyngeal and/or
109 oropharyngeal swabs from individuals who are suspected of COVID-19. The iAMP COVID-19
110 assay has the ability to detect SARS-CoV-2 RNA directly from samples without prior RNA
111 extraction process. All procedures as per manufacturer instructions were followed. The turnaround
112 time is 60 mins. It has received FDA emergency authorization for use.[10] In this method, the
113 control used is a human gene that is amplified and measured in the HEX channel. If a sample
114 shows no exponential amplification curve in the HEX channel but an exponential curve in the

115 FAM channel, the sample is still reported as a valid run and will be interpreted according to
116 manufacturers instructions. If there is no exponential amplification curve in any channel, the sample
117 test result is termed invalid.

118
119 **AQ-Top Plus COVID-19 Rapid Detection Kit:** [11] 226 samples were run through this kit. It is
120 a Real-Time Loop Mediated Isothermal Amplification (RT-LAMP) test intended for the
121 qualitative detection of nucleic acid from SARS-CoV-2 in clinical respiratory specimens like
122 nasopharyngeal swabs. The AQ-TOP COVID-19 Rapid Detection Kit PLUS uses dual-labeled
123 Peptide Nucleic Acid (PNA) probes that target ORF1ab and N gene for detection of SARS-CoV-
124 2 RNA. It has a fast turnaround time of 20 minutes. It has also received FDA emergency
125 authorization for use.[12] The results are interpreted as per manufacturer's instructions. If no
126 amplification curves are detected in both the FAM and VIC fluorescent channels or if an
127 amplification curve is detected but at a CT more than 30 the test is considered invalid.

128
129 **Direct Nasopharyngeal Swab (Direct NPS) Realtime RT-PCR [13]:** 200 samples were tested
130 by this method. The NPS samples collected were stored in the lab at -80 degree Celsius and was
131 run after few days. It is an RNA-extraction free, RT-qPCR method for SARS-CoV-2 detection.
132 The direct NPS method was tested with various transport media for direct lysis. Bio-Speedy Direct
133 RT-qPCR SARS-Cov-2 kit with the vNAT buffer contains guanidinium thiocyanate and was
134 validated with 50 samples. 90 samples were used to validate DIAGNOVITAL Magicprep fast
135 RNA isolation kit and 10 samples were validated with OriginSafe Viral Lysis Transport Kit, which
136 contains Viral Lysis Transport Medium (OriginSafe VLTM) that disrupts lipid membrane and
137 inactivates nucleases. All 3 kits were unsuccessful to produce a good quality extract and all tests

138 presented invalid results. However, direct lysis using proteinase K was relatively more successful
139 and was pursued for evaluation. Nasal Swabs are treated with proteinase K followed by a heat
140 inactivation step and is then directly added to the master mix for RT-qPCR. For best results,
141 optimization of the ratio of proteinase K and the sample mixture was done in the lab, testing five
142 different ratios starting from 5ul of the proteinase K with 50 ul of the sample sequentially to 40ul
143 of proteinase K and 15ul of sample mixture and the best correlation with the reference values were
144 attained at 15 ul of proteinase K with 40 ul sample. With this optimization further testing was
145 done, turnaround time is around 2 hours.

146
147 **Genechecker PCR system- UF 300 – RT PCR system [14]**– 1133 samples were tested in this
148 method. It is an innovative microfluidic chip-based PCR method with a compact device and ultra-
149 fast ramping of 40 cycles in 20 minutes through a unique thermal cycling mechanism. The kit has
150 been developed to detect both RdRP gene and N gene of SARS-COV-2. Two fluorescent channels
151 are used, FAM and ROX to detect the gene and to serve as an internal control respectively. The primer
152 pairs and probes for the detection of these two target genes are pre-labeled in the wells of the test chip so
153 that user does not have to pipette primers and probes for running the test. Four samples can be tested per
154 run and the standard turnaround time is 45 minutes with 10 – 15 minutes of preparation.

155 The results are displayed on screen as either N gene and RdRP gene detected or not detected along
156 with the control validity. This makes the reporting easier, and it also displays the amplification
157 curves for easier reading. The positive control should be positive, and template control should be
158 negative to confirm the test validity, if not the test is reported invalid.

159

160 **Cobas Liat system SARS-CoV-2 & Influenza A/B nucleic acid test [15]:** 524 samples were
161 tested with this method. It is an automated multiplex real-time RT-PCR assay for in-vitro
162 qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B virus RNA
163 in nasopharyngeal and nasal swabs. The assay targets both the ORF1 a/b non-structural region and
164 nucleocapsid protein gene that are unique to SARS-CoV-2. An Internal Process Control (IPC) is
165 present to control for adequate processing of the target virus through steps of sample purification,
166 nucleic acid amplification, and to monitor the presence of inhibitors in the RT-PCR processes. The
167 results are displayed as SARS-CoV-2 detected, not detected or invalid within 20 minutes. It has
168 got FDA emergency authorization for use. [16]

169 **POCKIT SARS-CoV-2 (orf lab) (RT-ii PCR) assay [17]**

170 It is a PCR test for qualitative detection of SARS-CoV-2 from nasopharyngeal swabs and 2212
171 samples were tested with this method. It uses the insulated isothermal polymerase chain reaction
172 (iiPCR) technology and must be used with a POCKIT Central Nucleic Acid Analyzer. It generates
173 fluorescent signals, 520 nm and 550 nm, when the specific nucleic acid sequences of SARS-CoV-
174 2 and the internal Control are amplified, respectively. When both the 520 nm and 550 nm signals
175 are positive the sample is interpreted positive for SARS-COV-2 and when 520 nm is negative, and
176 550 nm is positive the sample is termed negative for SARS-COV-2 virus. When both signals are
177 negative or not detected it is termed invalid.

178

179 **Statistical analysis**

180 The results of the standard RT – qPCR was used as a standard reference and the results obtained
181 from the rapid methods were compared to the standard reference reports.

182 Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and
183 accuracy were calculated for each method. Cohen's kappa values were calculated to measure
184 agreement, along with percent positive agreement (PPA), negative agreement percent (NPA) and
185 overall agreement were calculated. SPSS statistical software was used for all statistical analysis.

186

187

188 **Results**

189 The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and
190 accuracy were calculated for the seven rapid methods by comparing with the standard RT-PCR
191 results. The results are shown in figure 1. (Figure 1)

192 AQ-TOP and Genechecker had the highest sensitivity and positive predictive value followed by
193 sensitivity of Abbott ID NOW and Cobas Liat. The Direct NPS RT-qPCR method and Atila had
194 the lowest sensitivity. The POCKIT had the highest accuracy followed by Genechecker and Cobas
195 Liat.

196 The positive, negative, and overall agreement percentage along with Cohens' kappa value were
197 calculated for the seven methods and are presented in Table 1.

198 The positive percentage agreement with the standard RT-qPCR was strongest with AQ-Top
199 followed by Genechecker. Similarly, the negative agreement was best with POCKIT, Cobas Liat
200 and Genechecker. AQTOP. The overall agreement was highest in POCKIT and the overall
201 agreement percentage was poor in Direct PCR and Atila iAMP.

202 The number of positive cases missed, and details of the results reported invalid by the rapid tests
203 are shown in Table 2. Atila iAMP showed the highest percentage of invalid reports missing a large
204 proportion (44.7%) of positive cases followed by AQ-TOP with 7% invalid reports. The Direct
205 NPS- RT-PCR and Cobas Liat did not show any invalid reports.

206 **Discussion**

207 In this ongoing COVID-19 pandemic with extensive transmission of infection, rapid molecular
208 tests are very crucial for early identification and isolation. The molecular assays evaluated in this
209 study are all rapid with low complexity thus requires less hands-on time, which is the need of the
210 hour hence assays were evaluated in comparison to the standard RT-PCR.

211 Our study found that the sensitivity of the Atila iAMP assay and Direct lysis RT-PCR method for
212 nasopharyngeal swab RT-qPCR was very low. While some studies have demonstrated no
213 substantial difference in sensitivity for direct NPS method when compared to standard RT-qPCR
214 for molecular detection of SARS-CoV-2 [18], there are also evidences that show, amplification
215 directly from samples can reduce efficiency of PCR. [19]. This can be attributed to the presence
216 of inhibitors that interferes with the polymerase activity and decrease the sensitivity and accuracy
217 of detection. [20] Another reason may be due to inadequate extraction quality in the direct method,
218 further the samples that were used in this study for the direct NPS RT-qPCR method were stored
219 in the lab at -80 degrees Celsius for 3 – 4 days. This might be one of the reasons for low sensitivity
220 as a study done in Germany has shown that direct NPS performs better when the samples are fresh
221 and RNA extraction would be required if the samples are stored longer. [21]

222 The Atila iAMP assay has been claimed to have around 87% PPA and 100% NPA with the
223 reference RT-PCR assay. [22], but in this study we found that the sensitivity was very low, and it

224 reported a large number of invalid results, missing more than 40 % of positive cases when
225 compared to the standard RT-qPCR results. The agreement percentage (kappa agreement) with the
226 NPS results was low. In this assay, 93 positive samples were reported as either negative or invalid
227 and the mean Ct value of these positive samples were 31.54 ± 4.84 . The test missed weak/ low viral
228 load samples, that had Ct values more than 30. This was supported by the study in Stanford, that
229 showed Atila had lower sensitivity and required high volume of nucleic acid eluate. [22] Further
230 studies have shown that molecular tests using the LAMP technology have reported false negative
231 results in low viral load. [23] However the assay showed high specificity which can be explained
232 by the four different primers that are used in this assay to detect six different sequences of the
233 RNA of SARS-COV-2. [24] Also the test does not require RNA extraction prior to amplification,
234 thus reducing the time to run along with the ability to process 96 samples per run and providing
235 the results within 60 minutes. While there are positive aspects, the sensitivity and reliability of the
236 method are important parameters for screening, hence with lower sensitivity higher percentages of
237 false negative results would be expected and the high percentage of invalid results makes the test
238 less reliable as a rapid method, for these reasons the test cannot be widely employed as a screening
239 test.

240 In our study the Abbott and AQ-TOP both used the LAMP technology and had high sensitivity,
241 specificity, PPA, NPA and the kappa coefficient was strong. Similar studies have reported LAMP
242 assays to be identical with the RT-PCR tests and reported similar sensitivity and specificity [25]
243 The drawback of AQ - TOP was that it showed 6% invalid reports, which is a relatively high
244 number compared to other tests. But this method is quick with faster amplification and high
245 throughput, 96 samples can be tested in each run, results are easily readable and requires less

246 specialized equipment. It further has the ability for amplification of multiple targets in a single
247 reaction.[26]

248 The Abbott ID NOW had an accuracy of 96.5%, with sensitivity and specificity comparable to the
249 standard RT – qPCR and lowest percentage of invalid reports compared to other methods. It also
250 showed a strong agreement with the RT-PCR results. A study by Rhoads in the USA reported
251 similar findings, which showed that the assay had a good PPA of 94%. [27] Another study done
252 in New York had shown that when compared to Xpert Xpress, ID NOW revealed good PPA only
253 when sample had low Ct values and the PPA was low in the higher Ct values samples or when the
254 viral load was low. [28] Similar reports were published by another study that validated RT-LAMP,
255 which showed that samples having Ct values less than 30 showed 100% sensitivity, while samples
256 with Ct values more than 35 showed only 54% concordance with the RT-qPCR results.[29]
257 However in our study, we found that the concordance with the RT- qPCR results did not change
258 with the Ct values. Further, the Abbott ID is compact, can be used as a bedside test and it is rapid
259 as it detects the positive results in just 7 minutes and negative results in 13 minutes, although only
260 one sample can be tested per run.

261 The Genechecker had a high sensitivity and concordance with the RT-qPCR reports, with the least
262 percentage of invalid reports. It has statistically significant 0.938 Cohen’s kappa value and thereby
263 strong agreement with the results of the standard reference test. Further this method has a
264 turnaround time of 45 minutes and 4 samples can be tested per run. But the preparation of the
265 samples requires 5 to 10 minutes and requires manual pipetting which is recommended to be done
266 in a biosafety cabinet. Therefore, though Genechecker is a compact instrument cannot be used as
267 a bedside test. Also for efficient usage four samples need to be run together as there would be

268 wastage of the kit cartridges. There aren't many studies on the evaluation of Genechecker but our
269 study shows the method has great potential as a rapid detection method.

270 The Cobas Liat automated RT-PCR showed the PPA of 94.5 % and accuracy of 97.5% with the
271 lowest PPV of 76% and the results can be obtained in 20 minutes . Another study that evaluated
272 the clinical performance of Cobas Liat showed that its accuracy was 98.6%, positive percent
273 agreement was 100% and the negative percent agreement was 97.4%. which was very similar to
274 our study report. [30] However a recent report warns of potential false positives with Cobas rapid
275 test that was alleged to sporadic assay tube leakage or abnormal PCR cycling in the reaction tubes.
276 [31] This might explain the high false positives and lowest PPV observed in our study with Cobas
277 Liat.

278 The POKKIT SARS-CoV-2 (orf lab) (RT-ii PCR) assay had the highest overall agreement with
279 the reference RT-PCR method. The turnaround time is 85 minutes with a throughput of 8 samples
280 per run. The positive A study that validated its clinical performance comparing it to standard RT-
281 PCR assay also showed that positive agreement was 96.8% and kappa value of 0.93. [32] However
282 in our study the positive agreement was only 90% this might be because the number of positive
283 samples tested were only 75 samples compared to 2137 negative reports. The test reported high
284 number of invalid reports which was 3.7 % of the total samples.

285 **Strengths and limitations**

286 The study has evaluated commercial assays available in the market for rapid detection of SARS-
287 COV-2, which is the need of the hour. All the results are compared to the gold standard RT- PCR
288 recommended for SARS-COV-2 detection, which gives an insight of the performance of these
289 rapid methods based on the standard comparison.

290 The limitation is that the number of samples tested with each rapid method varies, which was based
291 on the availability of kits and reagents.

292 **Conclusion**

293 In summary, the evaluation of seven rapid methods of detection of SARS-COV-2 using NPS shows
294 that the direct (extraction free) NPS method and Atila had low sensitivity, along with the high
295 number of invalid reports with Atila, which made the test unreliable. While AQ-TOP had good
296 sensitivity and rapid turnaround time of 20 minutes but again the percentage of invalid reports
297 were high using this method. The POCKIT had highest overall agreement percentage but with
298 lower sensitivity than most other rapid tests and high number of invalid reports. AQ-TOP, Abbott
299 and GeneChecker had high sensitivity a strong kappa value and rapid turnaround time of 20, 15
300 and 45 minutes, respectively. Cobas Liat, Abbott ID NOW and Genechecker system had the least
301 number of invalid reports however the throughput for each is 1,1 and 4 respectively. Further
302 studies reviewing of all these parameters are needed, to consider implementing these rapid tests in
303 large scale in detection of SARS-COV-2.

304 **Authors contribution:**

- 305 1. Sally A. Mahmoud: conceptualization, Methodology, validation, reviewing and editing,
306 supervision and project administration
- 307 2. Esra Ibrahim : Conceptualization, Methodology, validation, reviewing and editing
- 308 3. Subhashini Ganesan: Conceptualization, Methodology, writing original draft, validation,
309 reviewing and editing
- 310 4. Bhagyashree Thakre: Methodology, validation, reviewing and editing
- 311 5. Juliet G Teddy: Methodology, validation, reviewing and editing
- 312 6. Preeti Raheja: Methodology, validation, reviewing and editing
- 313 7. Walid Z Abbas: Reviewing, editing, supervision and project administration

314 **Funding statement**

315 The study was not funded by any funding body, it was done in Biogenix lab as a part of research.

316 **Ethics approval and consent to participate.**

317 The Ethics approval was obtained from Department of Health (DOH) Institutional review board
318 (IRB), Abu Dhabi. All methods were carried out in accordance with relevant guidelines and
319 regulations. The Department of Health (DOH) Institutional review board (IRB), Abu Dhabi.

320 **Informed consent statement**

321 Informed consent was obtained from all participants in the study.

322 **Data Availability**

323 The data is available with the corresponding author, Dr. Sally, Director of Biogenix G42 lab and
324 will be produced on request.

325 **Conflict of interest**

326 The authors declare that they have no conflict of interest regarding the publication of this paper.

327 **References**

- 328 1. Worldometers. 2020. Available at: <https://www.worldometers.info/coronavirus/country/>
329 (Accessed on 23rd February 2020)
- 330 2. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink
331 S, Schneider J, Schmidt ML, Mulders DG. Detection of 2019 novel coronavirus (2019-
332 nCoV) by real-time RT-PCR. Eurosurveillance. 2020 Jan 23;25(3):2000045.
- 333 3. WHO (World Health Organization) Laboratory testing strategy recommendations for
334 COVID-19. Interim guidance. 2020. Available at:

- 335 https://apps.who.int/iris/bitstream/handle/10665/331509/WHO-COVID-19-lab_testing-
336 [2020.1-eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/331509/WHO-COVID-19-lab_testing-2020.1-eng.pdf) (Accessed 12 December 2020)
- 337 4. Nguyen T, Duong Bang D, Wolff A. 2019 novel coronavirus disease (COVID-19): paving
338 the road for rapid detection and point-of-care diagnostics. *Micromachines*. 2020
339 Mar;11(3):306.
- 340 5. Andersen, K.G., Rambaut, A., Lipkin, W.I. et al. The proximal origin of SARS-CoV-2.
341 *Nat Med* 26, 450–452 (2020). <https://doi.org/10.1038/s41591-020-0820-9>
- 342 6. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, Niemeyer D,
343 Jones TC, Vollmar P, Rothe C, et al. 2020. Virological assessment of hospitalized patients
344 with COVID-2019. *Nature* doi:10.1038/s41586-020-2196-x
- 345 7. Abbott Launches Molecular Point-of-Care Test to Detect Novel Coronavirus in as Little as
346 Five Minutes. Available online: [https://abbott.mediaroom.com/2020-03-27-Abbott-](https://abbott.mediaroom.com/2020-03-27-Abbott-Launches-Molecular-Point-of-Care-Test-to-Detect-Novel-Coronavirus-in-as-Little-as-Five-Minutes)
347 [Launches-Molecular-Point-of-Care-Test-to-Detect-Novel-Coronavirus-in-as-Little-as-](https://abbott.mediaroom.com/2020-03-27-Abbott-Launches-Molecular-Point-of-Care-Test-to-Detect-Novel-Coronavirus-in-as-Little-as-Five-Minutes)
348 [Five-Minutes](https://abbott.mediaroom.com/2020-03-27-Abbott-Launches-Molecular-Point-of-Care-Test-to-Detect-Novel-Coronavirus-in-as-Little-as-Five-Minutes) (accessed on 2 April 2020).
- 349 8. US Food and Drug Administration (FDA). ID NOW COVID-19. Letter of
350 Authorization. 2020. Available at: <https://www.fda.gov/media/136522/download>
- 351 9. Atila Biosystems. iAMP COVID-19 Detection Kit. Available at:
352 <https://atilabiosystems.com/our-products/covid-19/>
- 353 10. US Food and Drug Administration (FDA). Atila Biosystems - iAMP COVID-19 Detection
354 Kit. Available at: <https://www.fda.gov/media/136870/download>
- 355 11. Season Biomaterials. AQ- TOP COVID-19 rapid series. Available at:
356 <http://seasunbio.muee.co.kr/ko/?c=177&s=&gp=1&gbn=viewok&ix=272>

- 357 12. US Food and Drug Administration (FDA). AQ-TOP™ COVID-19 Rapid Detection Kit
358 PLUS. 2020. <https://www.fda.gov/media/142800/download>
- 359 13. Genoud V, Stortz M, Waisman A, Berardino BG, Verner P, Dansey V, Salvatori M,
360 Lenicov FR, Levi V. Extraction-free protocol combining Proteinase K and heat inactivation
361 for detection of SARS-CoV-2 by RT-qPCR. medRxiv. 2020 Jan 1.
- 362 14. Global Innovation Exchange. Genechecker UF- 300 by Genesystem. Available at:
363 [https://www.globalinnovationexchange.org/innovation/genechecker-uf-300-by-](https://www.globalinnovationexchange.org/innovation/genechecker-uf-300-by-genesystem)
364 [genesystem](https://www.globalinnovationexchange.org/innovation/genechecker-uf-300-by-genesystem)
- 365 15. Cobas SARS-CoV-2 & Influenza A/B Assay. Available at:
366 [https://diagnostics.roche.com/global/en/products/params/cobas-sars-cov-2-influenza-a-b-](https://diagnostics.roche.com/global/en/products/params/cobas-sars-cov-2-influenza-a-b-nucleic-acid-test.html)
367 [nucleic-acid-test.html](https://diagnostics.roche.com/global/en/products/params/cobas-sars-cov-2-influenza-a-b-nucleic-acid-test.html)
- 368 16. US Food and Drug Administration (FDA). <https://www.fda.gov/media/142193/download>
369 (cobas liat)
- 370 17. POCCKIT Central SARS-CoV-2 Premix Reagent- User manual. Available at:
371 [https://www.genereach.com/data/document%20download/common/Products/POCKIT%2](https://www.genereach.com/data/document%20download/common/Products/POCKIT%20Central%20SARS-CoV-2%20Premix%20Reagent%20%20User%20Manual%20(20200601)_US%20....pdf)
372 [0Central%20SARS-CoV-](https://www.genereach.com/data/document%20download/common/Products/POCKIT%20Central%20SARS-CoV-2%20Premix%20Reagent%20%20User%20Manual%20(20200601)_US%20....pdf)
373 [2%20Premix%20Reagent%20 %20User%20Manual%20\(20200601\)_US%20....pdf](https://www.genereach.com/data/document%20download/common/Products/POCKIT%20Central%20SARS-CoV-2%20Premix%20Reagent%20%20User%20Manual%20(20200601)_US%20....pdf)
- 374 18. Srivatsan S, Han PD, van Raay K, Wolf CR, McCulloch DJ, Kim AE, Brandstetter E,
375 Martin B, Gehring J, Chen W; Seattle Flu Study Investigators, Kosuri S, Konnick EQ,
376 Lockwood CM, Rieder MJ, Nickerson DA, Chu HY, Shendure J, Starita LM. Preliminary
377 support for a "dry swab, extraction free" protocol for SARS-CoV-2 testing via RT-qPCR.
378 bioRxiv [Preprint]. 2020 Apr 23:2020.04.22.056283. doi: 10.1101/2020.04.22.056283.
379 PMID: 32511368; PMCID: PMC7263496.

- 380 19. Wee SK, Sivalingam SP, Yap EPH. Rapid Direct Nucleic Acid Amplification Test without
381 RNA Extraction for SARS-CoV-2 Using a Portable PCR Thermocycler. *Genes*. 2020;
382 11(6):664. <https://doi.org/10.3390/genes11060664>
- 383 20. Hall, A.T.; Zovanyi, A.M.; Christensen, D.R.; Koehler, J.W.; Minogue, T.D. Evaluation of
384 Inhibitor-Resistant Real-Time PCR Methods for Diagnostics in Clinical and
385 Environmental Samples. *PLoS ONE* 2013, 8, e73845
- 386 21. Lübke N, Senff T, Scherger S, Hauka S, Andrée M, Adams O, Timm J, Walker A.
387 Extraction-free SARS-CoV-2 detection by rapid RT-qPCR universal for all primary
388 respiratory materials. *Journal of Clinical Virology*. 2020 Sep 1;130:104579
- 389 22. Bulterys PL, Garamani N, Stevens B, Sahoo MK, Huang C, Hogan CA, Zehnder J, Pinsky
390 BA. Comparison of a laboratory-developed test targeting the envelope gene with three
391 nucleic acid amplification tests for detection of SARS-CoV-2. *Journal of Clinical Virology*.
392 2020 Aug 1;129:104427.
- 393 23. Zhen W, Smith E, Manji R, Schron D, Berry GJ. Clinical evaluation of three sample-to-
394 answer platforms for detection of SARS-CoV-2. *Journal of clinical microbiology*. 2020 Jul
395 23;58(8).
- 396 24. Kitagawa, Y., Orihara, Y., Kawamura, R., Imai, K., Sakai, J., Tarumoto, N., ... Maeda, T.
397 (2020). Evaluation of rapid diagnosis of novel coronavirus disease (COVID-19) using
398 loop-mediated isothermal amplification. *Journal of Clinical Virology*,
399 104446. doi:10.1016/j.jcv.2020.104446
- 400 25. Yan C, Cui J, Huang L, Du B, Chen L, Xue G, Li S, Zhang W, Zhao L, Sun Y, et al. 2020.
401 Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse

- 402 transcription loop-mediated isothermal amplification assay. *Clin Microbiol Infect*
403 doi:10.1016/j.cmi.2020.04.001
- 404 26. 31Esbin MN, Whitney ON, Chong S, Maurer A, Darzacq X, Tjian R. Overcoming the
405 bottleneck to widespread testing: a rapid review of nucleic acid testing approaches for
406 COVID-19 detection. *Rna*. 2020 Jul 1;26(7):771-83.
- 407 27. Rhoads DD, Cherian SS, Roman K, Stempak LM, Schmotzer CL, Sadri N. Comparison of
408 Abbott ID Now, Diasorin Simplexa, and CDC FDA EUA methods for the detection of
409 SARS-CoV-2 from nasopharyngeal and nasal swabs from individuals diagnosed with
410 COVID-19. *Journal of clinical microbiology*. 2020 Apr 17
- 411 28. Basu A, Zinger T, Inglema K, Woo KM, Atie O, Yurasits L, See B, Agüero-Rosenfeld ME.
412 Performance of Abbott ID Now COVID-19 rapid nucleic acid amplification test using
413 nasopharyngeal swabs transported in viral transport media and dry nasal swabs in a New
414 York City academic institution. *Journal of clinical microbiology*. 2020 Jul 23;58(8).
- 415 29. Haq F, Sharif S, Khurshid A, Shabbir I, Salman M, Badar N, Ikram A, Ahad A, Malik MF.
416 Development Optimization and Validation of RT-LAMP based COVID-19 Facility in
417 Pakistan. *bioRxiv*. 2020 Jan 1.
- 418 30. Hansen G, Marino J, Wang ZX, Beavis KG, Rodrigo J, Labog K, Westblade LF, Jin R,
419 Love N, Ding K, Garg S, Huang A, Sickler J, Tran NK. Clinical Performance of the Point-
420 of-Care cobas Liat for Detection of SARS-CoV-2 in 20 Minutes: a Multicenter Study. *J*
421 *Clin Microbiol*. 2021 Jan 21;59(2):e02811-20.
- 422 31. US Food and Drug Administration (FDA). [https://www.fda.gov/medical-devices/letters-](https://www.fda.gov/medical-devices/letters-health-care-providers/potential-false-results-roche-molecular-systems-inc-cobas-sars-cov-2-influenza-test-use-cobas-liat?utm_medium=email&utm_source=govdelivery)
423 [health-care-providers/potential-false-results-roche-molecular-systems-inc-cobas-sars-](https://www.fda.gov/medical-devices/letters-health-care-providers/potential-false-results-roche-molecular-systems-inc-cobas-sars-cov-2-influenza-test-use-cobas-liat?utm_medium=email&utm_source=govdelivery)
424 [cov-2-influenza-test-use-cobas-liat?utm_medium=email&utm_source=govdelivery](https://www.fda.gov/medical-devices/letters-health-care-providers/potential-false-results-roche-molecular-systems-inc-cobas-sars-cov-2-influenza-test-use-cobas-liat?utm_medium=email&utm_source=govdelivery)

425 32. Chang PL, Lin CY, Chen CP, Lin YC, Hu HC, Cheng SH, Cheng CY. Clinical validation
426 of an automated reverse transcription-insulated isothermal PCR assay for the detection of
427 severe acute respiratory syndrome coronavirus 2. *Journal of Microbiology, Immunology*
428 *and Infection*. 2021 Feb 1.

429

430

431

432


433

434

435

436

437 **Figure 1: Comparison of the seven rapid methods of nucleic acid detection**



438

439

440 **Table 1 : Shows the agreement of the rapid tests results with the standard reference test**
 441 **results**

| Molecular assays (n) | Standard reference test | | Kappa (k) (p value) | Positive agreement (%) | Negative agreement (%) | Overall Agreement (%) |
|--------------------------------|-------------------------|----------|---------------------|------------------------|------------------------|-----------------------|
| | Positive | Negative | | | | |
| Direct NPS RT-PCR (200) | | | | | | |
| Positive | 31 | 0 | 0.398 | 36.47 | 100 | 73 |
| Negative | 54 | 115 | (<0.001) | | | |
| Atila iAMP (127) | | | | | | |
| Positive | 30 | 2 | 0.391 | 44.11 | 96.61 | 68.50 |
| Negative | 38 | 57 | (<0.001) | | | |
| AQ – Top (212) | | | | | | |
| Positive | 102 | 4 | 0.943 | 98.07 | 96.29 | 91.15 |
| Negative | 2 | 104 | (<0.001) | | | |

| Genechecker (1128) | | | | | | |
|--------------------------------|-----|------|----------|-------|-------|-------|
| Positive | 120 | 8 | 0.938 | 95.23 | 99.20 | 98.75 |
| Negative | 6 | 994 | (<0.001) | | | |
| Abbott ID NOW (686) | | | | | | |
| Positive | 158 | 16 | 0.906 | 95.18 | 96.92 | 96.50 |
| Negative | 8 | 504 | (<0.001) | | | |
| Cobas Liat (524) | | | | | | |
| Positive | 35 | 11 | 0.830 | 94.59 | 97.74 | 97.52 |
| Negative | 2 | 476 | (<0.001) | | | |
| POCKIT (2131) | | | | | | |
| Positive | 65 | 8 | 0.893 | 90.27 | 99.61 | 99.29 |
| Negative | 7 | 2051 | (<0.001) | | | |

442

443

444 **Table 2: Invalid reports and positive cases missed by the rapid methods.**

| Rapid methods (n) | Invalid reports (n(%)) | Positive cases reported by standard RT-qPCR missed by the rapid tests (n (%)) |
|--|-----------------------------------|--|
| Direct Nasopharyngeal Swab Realtime RT-PCR (200) | 0 | 0 |
| Atila iAMP COVID- 19 detection (197) | 70 (35.5) | 55 (44.7) |
| AQ-TOP COVID-19 Rapid Detection (226) | 14 (6.1) | 3 (2.8) |
| Genechecker- UF 300 – RT PCR system (1133) | 5 (0.4) | 5 (3.1) |
| The Abbott ID NOW COVID-19 assay (689) | 3 (0.4) | 2 (1.2) |

| | | |
|---|----------|---------|
| Cobas Liat (524) | 0 | 0 |
| POCKIT SARS-CoV-2 (orf lab) Premix Reagent (2212) | 81 (3.7) | 10(1.3) |

445